The NAME trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer

S. T. Langkjer, J. Kenholm, J. D. Jensen, K. Wedervang, A. T. Brixen, M. Grunnet, L. Stenbygaard, H. Dano, V. Glavicic, E. H. Jacobsen, A. S. Brems-Eskildsen, H. L. Kruse, T. Dongsgaard, J. Neimann, J. Geisler

Research output: Contribution to journalConference abstract in journal

Original languageEnglish
JournalAnnals of Oncology
Volume29
Issue numberSuppl. 8
Pages (from-to)viii120
Number of pages1
ISSN0923-7534
DOIs
Publication statusPublished - 1. Oct 2018
Event43rd ESMO Congress - Munich, Germany
Duration: 19. Oct 201823. Oct 2018

Conference

Conference43rd ESMO Congress
CountryGermany
CityMunich
Period19/10/201823/10/2018

Cite this

Langkjer, S. T., Kenholm, J., Jensen, J. D., Wedervang, K., Brixen, A. T., Grunnet, M., Stenbygaard, L., Dano, H., Glavicic, V., Jacobsen, E. H., Brems-Eskildsen, A. S., Kruse, H. L., Dongsgaard, T., Neimann, J., & Geisler, J. (2018). The NAME trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer. Annals of Oncology, 29(Suppl. 8), viii120. https://doi.org/10.1093/annonc/mdy272.354